An Estimation of the Risk of Pseudotumor Cerebri among Users of the Levonorgestrel Intrauterine Device. (4th July 2017)

• Record Type: Journal Article
• Authors: Valenzuela, Reuben M.; Rai, Ruju; Kirk, Brian H.; Sanders, Jessica N.; Sundar, Subhashree; Hamann, Steffen; Warner, Judith E. A.; Digre, Kathleen B.; Crum, Alison V.; Jones, Kirtly P.; Katz, Bradley J.
• Is Part Of: Neuro-ophthalmology. Volume 41:Number 4(2017)
• Page Start: 192
• Page End: 197
• Publication Date: 2017-07-04
• Subjects: Contraception -- idiopathic intracranial hypertension -- intrauterine system -- levonorgestrel -- pseudotumor cerebri; Neuroophthalmology -- Periodicals; 617.7
• DOI: 10.1080/01658107.2017.1304425
• Languages: English
• ISSNs: 0165-8107

Abstract

ABSTRACT: Because of a previous association of pseudotumor cerebri (PTC) with levonorgestrel, we wished to evaluate the use of levonorgestrel-eluting intrauterine devices ("levonorgestrel intrauterine systems", LNG-IUS) in our University of Utah and Rigshospitalet PTC patients. In our retrospective series, PTC prevalence was approximately 0.18% and 0.15% in the LNG-IUS population versus 0.02% and 0.04% in the non-LNG-IUS population (Utah and Rigshospitalet, respectively), with no significant differences in PTC signs and symptoms among the two groups. Our investigation suggests that women with an LNG-IUS may have increased risk of developing PTC but does not suggest an LNG-IUS can cause PTC.